Cd30⁺ cutaneous lymphoproliferative disorders: The stanford experience in lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma - 29/08/11

Doi : 10.1016/S0190-9622(03)02484-8

Howard L. Liu, MD ^a, Richard T. Hoppe, MD ^b, Sabine Kohler, MD ^c, Jeff D. Harvell, MD ^c, Sunil Reddy, MD ^d, Youn H. Kim, MD ^a,^⁎
^a Department ofDermatology, Stanford University, Stanford, California, USA
^b Department of Radiation Oncology, Stanford University, Stanford, California, USA
^c Department of Pathology, Stanford University, Stanford, California, USA
^d Department of Medicine, Division of Medical Oncology, Stanford University, Stanford, California, USA

^*Reprint requests: Youn H. Kim, MD, 900 Blake Wilbur Dr, W0075, Stanford, CA 94305, USA.

Abstract

Background

CD30⁺ cutaneous lymphoproliferative disorders (CLPDs) include lymphomatoid papulosis, borderline cases of CD30⁺ CLPDs, and primary cutaneous anaplastic large cell lymphoma (PCALCL). Prior studies have shown CD30⁺ CLPDs have an excellent prognosis.

Objective

We sought to present the single-center experience of Stanford University, Stanford, Calif, in the management of CD30⁺ CLPDs.

Methods

A retrospective cohort analysis of 56 patients with CD30⁺ CLPDs treated at our institution was performed.

Results

No patients with lymphomatoid papulosis died of disease, and overall survival was 92% at 5 and 10 years. Disease-specific survivals at 5 and 10 years for PCALCL were 85%. Disease-specific survival at 5 years for localized versus generalized PCALCL was 91% versus 50% (P = .31). PCALCL was highly responsive to treatment, but the relapse rate was 42%. In all, 3 patients progressed to extracutaneous stage of disease. No clinical or histologic factors analyzed were predictive of worse outcome in lymphomatoid papulosis and PCALCL.

Conclusion

Similar to prior reports from multicenter European groups, the single-center experience at our institution demonstrates CD30⁺ CLPDs have an overall excellent prognosis; however, cases of PCALCL with poor outcome do exist.

Le texte complet de cet article est disponible en PDF.

Abbreviations : ALCL, CHOP, CLPDs, CR, DSS, EXC, LyP, MF, PCALCL

Plan

Patients and methods

Patient selection

Histology

Survival, prognosis, and statistical analysis

Response to therapy

Results

Histology and immunohistochemistry

Clinical characteristics and course

Treatment and clinical response

Survival curves and predictors of survival

Discussion

Supported by the Stanford Cutaneous Lymphoma Research Fund.
Conflicts of interest: None identified.
Accepted for publication May 20, 2003.

Export

Vol 49 - N° 6

P. 1049-1058 - décembre 2003 Retour au numéro

Article précédent

Receive tables of contents by e-mail

| Article suivant

Differences and similarities among expert opinions on the diagnosis and treatment of pemphigus vulgaris
Daniel Mimouni, Carlos H. Nousari, Deborah L. Cummins, David J. Kouba, Michael David, Grant J. Anhalt

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

connectez-vous ou créez un compte

Cd30⁺ cutaneous lymphoproliferative disorders: The stanford experience in lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma - 29/08/11

Abstract

Background

Objective

Methods

Results

Conclusion

Plan

Export citations

Fichier

Contenu

Accès rapides

Mon compte

Aide & support

Plateformes Elsevier Masson

Déclaration CNIL